EA200800294A1 - Способы нейропротекции - Google Patents
Способы нейропротекцииInfo
- Publication number
- EA200800294A1 EA200800294A1 EA200800294A EA200800294A EA200800294A1 EA 200800294 A1 EA200800294 A1 EA 200800294A1 EA 200800294 A EA200800294 A EA 200800294A EA 200800294 A EA200800294 A EA 200800294A EA 200800294 A1 EA200800294 A1 EA 200800294A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- phenyl
- alkyl
- formula
- optionally substituted
- Prior art date
Links
- 230000004112 neuroprotection Effects 0.000 title abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69840305P | 2005-07-12 | 2005-07-12 | |
| PCT/US2006/026291 WO2007008562A2 (en) | 2005-07-12 | 2006-07-07 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200800294A1 true EA200800294A1 (ru) | 2008-06-30 |
Family
ID=37637734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200800294A EA200800294A1 (ru) | 2005-07-12 | 2006-07-07 | Способы нейропротекции |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20070021500A1 (https=) |
| EP (1) | EP1917009A2 (https=) |
| JP (1) | JP2009501224A (https=) |
| KR (1) | KR20080031951A (https=) |
| CN (1) | CN101287459A (https=) |
| AR (1) | AR054551A1 (https=) |
| AU (1) | AU2006269381A1 (https=) |
| BR (1) | BRPI0613006A2 (https=) |
| CA (1) | CA2615129A1 (https=) |
| CR (1) | CR9721A (https=) |
| EA (1) | EA200800294A1 (https=) |
| EC (1) | ECSP088179A (https=) |
| IL (1) | IL188729A0 (https=) |
| NI (1) | NI200800008A (https=) |
| NO (1) | NO20080738L (https=) |
| TW (1) | TW200800158A (https=) |
| WO (1) | WO2007008562A2 (https=) |
| ZA (1) | ZA200801401B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2385087T3 (es) * | 2005-07-26 | 2012-07-18 | Sk Biopharmaceuticals Co., Ltd | Procedimientos para tratar trastornos relacionados con sustancias |
| US9050005B2 (en) | 2005-08-25 | 2015-06-09 | Synapse Biomedical, Inc. | Method and apparatus for transgastric neurostimulation |
| WO2007103585A2 (en) * | 2006-03-09 | 2007-09-13 | Synapse Biomedical, Inc. | Ventilator assist system and method to improve respiratory function |
| US20080097153A1 (en) * | 2006-08-24 | 2008-04-24 | Ignagni Anthony R | Method and apparatus for grasping an abdominal wall |
| JP2010505856A (ja) * | 2006-10-06 | 2010-02-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | （ｓ）−（＋）−２−（２−クロロフェニル）−２−ヒドロキシ−エチルカルバメートの新規結晶 |
| US9079016B2 (en) * | 2007-02-05 | 2015-07-14 | Synapse Biomedical, Inc. | Removable intramuscular electrode |
| US9820671B2 (en) * | 2007-05-17 | 2017-11-21 | Synapse Biomedical, Inc. | Devices and methods for assessing motor point electromyogram as a biomarker |
| WO2009059033A1 (en) * | 2007-10-30 | 2009-05-07 | Synapse Biomedical, Inc. | Method of improving sleep disordered breathing |
| US8428726B2 (en) | 2007-10-30 | 2013-04-23 | Synapse Biomedical, Inc. | Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| KR101418061B1 (ko) * | 2012-09-28 | 2014-07-10 | 한국과학기술연구원 | 성상교세포의 글루타메이트 방출 기작 |
| CN105189451A (zh) | 2013-03-12 | 2015-12-23 | 比皮艾思药物研发有限公司 | 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| WO2017150903A1 (en) | 2016-02-29 | 2017-09-08 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| US11471683B2 (en) | 2019-01-29 | 2022-10-18 | Synapse Biomedical, Inc. | Systems and methods for treating sleep apnea using neuromodulation |
| KR20230044274A (ko) * | 2020-08-31 | 2023-04-03 | (주)바이오팜솔루션즈 | 신경퇴행성 질환의 예방 또는 치료용 페닐 알킬 카바메이트 화합물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| HUP0203198A3 (en) * | 1999-08-20 | 2005-07-28 | Ortho Mcneil Pharm Inc | Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use |
| EP1383489B1 (en) * | 2001-02-27 | 2007-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| DK1809273T3 (da) * | 2004-09-16 | 2010-08-02 | Janssen Pharmaceutica Nv | Anvendelse af 2-phenyl-1,2-ethandiol-(di)carbamater til behandling af epileptogenese |
| PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
-
2006
- 2006-07-06 US US11/481,601 patent/US20070021500A1/en not_active Abandoned
- 2006-07-07 WO PCT/US2006/026291 patent/WO2007008562A2/en not_active Ceased
- 2006-07-07 KR KR1020087003268A patent/KR20080031951A/ko not_active Withdrawn
- 2006-07-07 AU AU2006269381A patent/AU2006269381A1/en not_active Abandoned
- 2006-07-07 CN CNA2006800331046A patent/CN101287459A/zh active Pending
- 2006-07-07 EA EA200800294A patent/EA200800294A1/ru unknown
- 2006-07-07 CA CA002615129A patent/CA2615129A1/en not_active Abandoned
- 2006-07-07 BR BRPI0613006-2A patent/BRPI0613006A2/pt not_active IP Right Cessation
- 2006-07-07 JP JP2008521436A patent/JP2009501224A/ja not_active Withdrawn
- 2006-07-07 EP EP06786448A patent/EP1917009A2/en not_active Withdrawn
- 2006-07-11 TW TW095125161A patent/TW200800158A/zh unknown
- 2006-07-11 AR ARP060102977A patent/AR054551A1/es not_active Application Discontinuation
-
2008
- 2008-01-10 IL IL188729A patent/IL188729A0/en unknown
- 2008-01-11 NI NI200800008A patent/NI200800008A/es unknown
- 2008-02-11 ZA ZA200801401A patent/ZA200801401B/xx unknown
- 2008-02-11 NO NO20080738A patent/NO20080738L/no not_active Application Discontinuation
- 2008-02-11 CR CR9721A patent/CR9721A/es unknown
- 2008-02-12 EC EC2008008179A patent/ECSP088179A/es unknown
-
2009
- 2009-01-30 US US12/362,970 patent/US20090137652A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR9721A (es) | 2008-11-24 |
| CA2615129A1 (en) | 2007-01-18 |
| WO2007008562A3 (en) | 2007-08-16 |
| AU2006269381A1 (en) | 2007-01-18 |
| NI200800008A (es) | 2010-11-25 |
| US20070021500A1 (en) | 2007-01-25 |
| AR054551A1 (es) | 2007-06-27 |
| EP1917009A2 (en) | 2008-05-07 |
| KR20080031951A (ko) | 2008-04-11 |
| BRPI0613006A2 (pt) | 2010-12-14 |
| US20090137652A1 (en) | 2009-05-28 |
| ECSP088179A (es) | 2008-03-26 |
| ZA200801401B (en) | 2009-08-26 |
| IL188729A0 (en) | 2008-11-03 |
| TW200800158A (en) | 2008-01-01 |
| JP2009501224A (ja) | 2009-01-15 |
| WO2007008562A2 (en) | 2007-01-18 |
| CN101287459A (zh) | 2008-10-15 |
| NO20080738L (no) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| NI200800008A (es) | Métodos para la neuroprotección | |
| NO20080739L (no) | Fremgangsmater for behandling av Epileptogenese | |
| YU67703A (sh) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja | |
| NO20072444L (no) | Karbamatforbindelser for anvendelse i behandling av neurodegenerative forstyrrelser | |
| IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| EA200701536A1 (ru) | Способы контроля интервала qt | |
| ATE538784T1 (de) | Verfahren zur behandlung von substanzbedingten erkrankungen | |
| MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
| IL157594A0 (en) | Carbamate compounds for use in preventing or treating anxiety disorders | |
| CO6160292A2 (es) | Metodos de tratamiento de transtornos de comportamiento perturbador 877 | |
| IL159847A0 (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
| CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders |